Prognostic value of systemic inflammation-based markers in advanced pancreatic cancer

Internal Medicine Journal

Volumn 44, Issue 7, 2014, Pages 676-682

  Martin, H L ^a   Ohara, K ^a   Kiberu, A ^a   Van Hagen, T ^a   Davidson, A ^a   Khattak, M A ^a  

^a ROYAL PERTH HOSPITAL   (Australia)

Author keywords

Biomarker; Cancer; Chemotherapy; Inflammation; Pancreas; Prognosis

Indexed keywords

ALBUMIN; C REACTIVE PROTEIN; AUTACOID; BIOLOGICAL MARKER;

ADULT; AGED; ARTICLE; CANCER PROGNOSIS; FEMALE; GLASGOW PROGNOSTIC SCORE; HUMAN; INFLAMMATION; MAJOR CLINICAL STUDY; MALE; MEDICAL PARAMETERS; NAMED INVENTORIES, QUESTIONNAIRES AND RATING SCALES; NEUTROPHIL LYMPHOCYTE RATIO; PANCREAS CANCER; PLATELET LYMPHOCYTE RATIO; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SURVIVAL RATE; SURVIVAL TIME; BLOOD; MIDDLE AGED; MORTALITY; PANCREATIC NEOPLASMS; PROGNOSIS; TRENDS; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; BIOLOGICAL MARKERS; FEMALE; HUMANS; INFLAMMATION; INFLAMMATION MEDIATORS; MALE; MIDDLE AGED; PANCREATIC NEOPLASMS; PROGNOSIS; RETROSPECTIVE STUDIES; SURVIVAL RATE;

EID: 84903825223     PISSN: 14440903     EISSN: 14455994     Source Type: Journal    
DOI: 10.1111/imj.12453     Document Type: Article

References (40)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin 2011; 61: 69-90.
2. Conroy T, Desseigne F, Ychou M, Bouche O, Guimbaud R, Becouarn Y etal. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med 2011; 364: 1817-1825.
3. Von Hoff DD, Ervin T, Arena FP, Chiorean G, Infante J, Moore M etal. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med 2013; 369: 1691-1703.
4. Fortner JG, Klimstra DS, Senie RT, Maclean BJ. Tumor size is the primary prognosticator for pancreatic cancer after regional pancreatectomy. Ann Surg 1996; 223: 147-153.
5. Griffanti-Bartoli F, Arnone GB, Ceppa P, Ravera G, Carrabetta S, Civalleri D. Malignant tumors in the head of the pancreas and the periampullary region. Diagnostic and prognostic aspects. Anticancer Res 1994; 14: 657-666.
6. Raut CP, Tseng JF, Sun CC, Wang H, Wolff RA, Crane CH etal. Impact of resection status on pattern of failure and survival after pancreaticoduodenectomy for pancreatic adenocarcinoma. Ann Surg 2007; 246: 52-60.
7. Ozaki H, Hiraoka T, Mizumoto R, Matsuno S, Matsumoto Y, Nakayama T etal. The prognostic significance of lymph node metastasis and intrapancreatic perineural invasion in pancreatic cancer after curative resection. Surg Today 1999; 29: 16-22.
8. Dvorak HF. Tumors: wounds that do not heal. Similarities between tumor stroma generation and wound healing. N Engl J Med 1986; 315: 1650-1659.
9. Coussens LM, Werb Z. Inflammation and cancer. Nature 2002; 420: 860-867.
10. Balkwill F, Mantovani A. Inflammation and cancer: back to Virchow? Lancet 2001; 357: 539-545.
11. Mantovani A, Allavena P, Sica A, Balkwill F. Cancer-related inflammation. Nature 2008; 454: 436-444.
12. McKay CJ, Glen P, McMillan DC. Chronic inflammation and pancreatic cancer. Best Prac Res Clin Gastroenterol 2008; 22: 65-73.
13. Guthrie GJ, Charles KA, Roxburgh CS, Horgan PG, McMillan DC, Clarke SJ. The systemic inflammation-based neutrophil-lymphocyte ratio: experience in patients with cancer. Crit Rev Oncol Hematol 2013; 88: 218-230.
14. Proctor MJ, Morrison DS, Talwar D, Balmer SM, O'Reilly DS, Foulis AK etal. An inflammation-based prognostic score (mGPS) predicts cancer survival independent of tumour site: a Glasgow Inflammation Outcome Study. Br J Cancer 2011; 104: 726-734.
15. Garcea G, Ladwa N, Neal CP, Metcalfe MS, Dennison AR, Berry DP. Preoperative neutrophil-to-lymphocyte ratio (NLR) is associated with reduced disease-free survival following curative resection of pancreatic adenocarcinoma. World J Surg 2011; 35: 868-872.
16. Wang DS, Luo HY, Qiu MZ, Wang ZQ, Zhang DS, Wang FH etal. Comparison of the prognostic values of various inflammation based factors in patients with pancreatic cancer. Med Oncol 2012; 29: 3092-3100.
17. Smith RA, Bosonnet L, Raraty M, Sutton R, Neoptolemos JP, Campbell F etal. Preoperative platelet-lymphocyte ratio is an independent significant prognostic marker in resected pancreatic ductal adenocarcinoma. Am J Surg 2009; 197: 466-472.
18. Raungkaewmanee S, Tangjitgamol S, Manusirivithaya S, Srijaipracharoen S, Thavaramara T. Platelet to lymphocyte ratio as a prognostic factor for epithelial ovarian cancer. J Gynecol Oncol 2012; 23: 265-273.
19. Kasymjanova G, MacDonald N, Agulnik JS, Cohen V, Pepe C, Kreisman H etal. The predictive value of pre-treatment inflammatory markers in advanced non-small-cell lung cancer. Curr Oncol 2010; 17: 52-58.
20. Onodera T, Goseki N, Kosaki G. [Prognostic nutritional index in gastrointestinal surgery of malnourished cancer patients]. Nihon Geka Gakkai Zasshi 1984; 85: 1001-1005.
21. Bhatti I, Peacock O, Lloyd G, Larvin M, Hall RI. Preoperative hematologic markers as independent predictors of prognosis in resected pancreatic ductal adenocarcinoma: neutrophil-lymphocyte versus platelet-lymphocyte ratio. Am J Surg 2010; 200: 197-203.
22. Stotz M, Gerger A, Eisner F, Szkandera J, Loibner H, Ress AL etal. Increased neutrophil-lymphocyte ratio is a poor prognostic factor in patients with primary operable and inoperable pancreatic cancer. Br J Cancer 2013; 109: 416-421.
23. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 2011; 144: 646-674.
24. Gabay C, Kushner I. Acute-phase proteins and other systemic responses to inflammation. N Engl J Med 1999; 340: 448-454.
25. Zahorec R. Ratio of neutrophil to lymphocyte counts - rapid and simple parameter of systemic inflammation and stress in critically ill. Bratisl Lek Listy 2001; 102: 5-14.
26. Kusumanto YH, Dam WA, Hospers GA, Meijer C, Mulder NH. Platelets and granulocytes, in particular the neutrophils, form important compartments for circulating vascular endothelial growth factor. Angiogenesis 2003; 6: 283-287.
27. Motomura T, Shirabe K, Mano Y, Muto J, Toshima T, Umemoto Y etal. Neutrophil-lymphocyte ratio reflects hepatocellular carcinoma recurrence after liver transplantation via inflammatory microenvironment. J Hepatol 2013; 58: 58-64.
28. Fogar P, Sperti C, Basso D, Sanzari MC, Greco E, Davoli C etal. Decreased total lymphocyte counts in pancreatic cancer: an index of adverse outcome. Pancreas 2006; 32: 22-28.
29. Salazar-Onfray F, Lopez MN, Mendoza-Naranjo A. Paradoxical effects of cytokines in tumor immune surveillance and tumor immune escape. Cytokine Growth Factor Rev 2007; 18: 171-182.
30. Bellone G, Turletti A, Artusio E, Mareschi K, Carbone A, Tibaudi D etal. Tumor-associated transforming growth factor-beta and interleukin-10 contribute to a systemic Th2 immune phenotype in pancreatic carcinoma patients. Am J Pathol 1999; 155: 537-547.
31. Romano F, Uggeri F, Crippa S, Di Stefano G, Scotti M, Scaini A etal. Immunodeficiency in different histotypes of radically operable gastrointestinal cancers. J Exp Clin Cancer Res 2004; 23: 195-200.
32. Alexandrakis MG, Passam FH, Moschandrea IA, Christophoridou AV, Pappa CA, Coulocheri SA etal. Levels of serum cytokines and acute phase proteins in patients with essential and cancer-related thrombocytosis. Am J Clin Oncol 2003; 26: 135-140.
33. Klinger MH, Jelkmann W. Role of blood platelets in infection and inflammation. J Interferon Cytokine Res 2002; 22: 913-922.
34. Shimada H, Oohira G, Okazumi S, Matsubara H, Nabeya Y, Hayashi H etal. Thrombocytosis associated with poor prognosis in patients with esophageal carcinoma. J Am Coll Surg 2004; 198: 737-741.
35. Qian X, Tuszynski GP. Expression of thrombospondin-1 in cancer: a role in tumor progression. Proc Soc Exp Biol Med 1996; 212: 199-207.
36. Dabrow MB, Francesco MR, McBrearty FX, Caradonna S. The effects of platelet-derived growth factor and receptor on normal and neoplastic human ovarian surface epithelium. Gynecol Oncol 1998; 71: 29-37.
37. Stone RL, Nick AM, McNeish IA, Balkwill F, Han HD, Bottsford-Miller J etal. Paraneoplastic thrombocytosis in ovarian cancer. N Engl J Med 2012; 366: 610-618.
38. Roxburgh CS, McMillan DC. Role of systemic inflammatory response in predicting survival in patients with primary operable cancer. Future Oncol 2010; 6: 149-163.
39. McMillan DC. The systemic inflammation-based Glasgow Prognostic Score: a decade of experience in patients with cancer. Cancer Treat Rev 2013; 39: 534-540.
40. Chua W, Charles KA, Baracos VE, Clarke SJ. Neutrophil/lymphocyte ratio predicts chemotherapy outcomes in patients with advanced colorectal cancer. Br J Cancer 2011; 104: 1288-1295.